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Abstract   
Background: Pneumococcal disease constitutes a major global health problem. Adults aged 
over 50 and younger adults with specific chronic health conditions are at risk for invasive 
 pneumococcal disease, associated with substantial morbidity and mortality. In Europe, two 
vaccine types are used in adults for pneumococcal immunization: pneumococcal polysaccharide 
vaccine (PPV23) and pneumococcal conjugate vaccine (PCV13).   
Aims: To provide an overview and to compare the national guidelines for pneumococcal 
immunization for adults in Europe.  
Sources: In November 2016, national guidelines on pneumococcal vaccination for adults of 31  
European countries were obtained by Google search, the website of European Centre for 
Disease Prevention and Control and contacting public health officials. In our analysis we 
distinguished between age-based and risk-based guidelines. In October 2017, we used the same 
method to retrieve guideline updates.  
Content: We observed great variability regarding age, risk groups, vaccine type and use of 
boosters. In age-based guidelines, vaccination is mostly recommended in adults aged over 65 
using PPV23. Boosters are generally not recommended. An upper age limit for vaccination is 
reported in three countries. In the immunocompromised population, vaccination with both 
vaccines and administration of a booster is mostly recommended. In the population with chronic 
health conditions, there is more heterogeneity according vaccine type, sequence and 
administration of boosters. Asplenia is the only comorbidity for which all countries recommend 
vaccination.  
Implications: The great variability in European pneumococcal vaccination guidelines warrants 
European unification of the guidelines for better control of pneumococcal disease.   
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Introduction  
  
Pneumococcal infections constitute a major global health problem. It leads to a number of 
diseases like otitis media, pneumonia, meningitis and bacteremia. (1) The most frequent 
 manifestation of pneumococcal disease in adults is pneumonia, where Streptococcus 
pneumoniae is responsible for up to 60% of the cases of community-acquired pneumonia. (2)  
  
In the United States, data of the Centers for Disease Control and Prevention showed 17 cases 
of invasive pneumococcal disease (IPD) per 100.000 persons in all age groups. (3)  In England 
and Wales an incidence of IPD of 7 per 100.000 persons in all age groups is reported, and an 
incidence of 21 per 100.000 in persons aged 65 and older. (2)  
Risk groups for developing pneumococcal infections and complications are children aged <2 
years, adults aged 50 and older, and persons with specific comorbidities. (1)  Case fatality rate 
of IPD may reach 15-20% in adults and even 30-40% in elderly. (4, 5)   
  
The pneumococcus is a common human commensal in the nasopharynx, with asymptomatic 
carriage reported from 5% to 93% in all age groups. Carriage diminishes greatly with age: 
whereas up to 60% of the school-aged children may be colonized, only 5-10% of adults and 
<5% of nursing home residents are. (2, 3, 6, 7)  S. pneumoniae is classified by the presence of 
capsular polysaccharides, with at least 93 different serotypes identified. Up to 60% of the IPD 
infections (in Belgium even up to 83%) are caused by serotypes covered by PPV23. (5, 8)    
Currently, two different pneumococcal vaccines are approved for use in adults: the 
polysaccharide vaccine containing 23 different capsular polysaccharides (PPV23) and the 
conjugate vaccine containing 13 serotypes of S. pneumoniae (PCV13). (9) The PPV23 triggers 
a T-cell independent immune response with serotype-specific antibody formation. Although the 
PPV23 offers an extended serotype coverage, much of the antibody-response after vaccination 
is transitory, resulting in a decline in protection after 2-4 years. Also, immunogenicity is 
probably lower among young children, elderly, and immunocompromised persons. (10, 14) 
PCV13 triggers a T-cell dependent immune response, with formation of both serotype-specific 
antibodies and B memory cells, resulting in a better immune response. (10) As PCV13 
 stimulates the formation of mucosal antibodies and thus prevents acquisition of nasal carriage 
of vaccine types, a reduced spread by children of the serotypes included in PCV13 was 
observed, thereby protecting unvaccinated individuals in all age groups (‘herd protection  
effect’). (3)  
  
As the global burden of pneumococcal disease is high, most European countries have 
implemented national vaccination guidelines. However, the immunization guidelines vary 
greatly among countries in Europe in terms of age and risk groups for vaccination. (1) The aim 
of this review is to provide an overview and compare the national guidelines in Europe for 
pneumococcal immunization in adults.  
  
    
Methods  
Search strategy  
A two-fold search strategy was conducted in November 2016 to identify the national guidelines 
on pneumococcal vaccination for adults aged ≥ 18 years in 31 European countries. 
Immunization schedules for patients with hematological stem cell transplantation were 
excluded, as this was outside the scope of our review. Firstly, we used the Vaccine Schedule on 
the website of the European Centre for Disease Prevention and Control (ECDC; 
www.ecdc.europa.eu), and searched the reference websites provided for each country to obtain 
their official immunization guidelines. If no vaccination guidelines could be retrieved for a 
country by using this method, we performed a Google search (“pneumococcal vaccination 
guidelines adult [Name of the country]”, translated in the official language of this country by 
using Google Translate). In case both search strategies failed, we contacted the public health 
 officials of this country (as was the case for Bulgaria, Cyprus, Croatia and Estonia). In October 
2017, we used the same method to retrieve guideline updates.  
  
Data extraction  
To translate the vaccination guidelines from their original language, Google Translate or 
interpreters were used.    
Data were extracted in Word and Excel tables to synthesize information regarding study 
characteristics, vaccine type, sequence of vaccination, and use of boosters (supplementary 
tables 1-3 and tables 1-2). In our analysis, we distinguished between age-based and risk-based 
guidelines. In the risk-based guidelines, we beheld three different risk groups: patients with 
specific chronic health conditions, an immunocompromised group, and patients with other 
predisposing risk factors for pneumococcal disease. The risk factor-based guidelines concern 
all adults aged 18 years and older, unless otherwise specified in supplementary table 3.   
  
Data synthesis and analysis  
For the age-based guidelines and the different risk factors, we calculated the absolute numbers 
and percentages of vaccine and booster recommendation, and vaccine type used (table 1-2).  
This data extraction was performed by one researcher (CB) and verified by a second researcher 
(DM).     
     
 Results  
  
Identification of national vaccination guidelines   
We were able to identify guidelines for adult pneumococcal immunization for 28 of the 31 
reviewed European countries (90%). No guidelines were found for Cyprus, Latvia, and 
Romania. In all of the 28 countries, risk-based guidelines were available, while age-based 
guidelines were available in 27 countries (96%). No age-based guidelines were found for 
Croatia.  More than 90% of these countries (93%; n=26) updated their guidelines in 2014 or  
later.    
In both age- and risk-based guidelines, a great variability was observed regarding to the age 
group eligible for vaccination and the type of recommended vaccine (see supplementary table 2-3 
and table 1-2)  
  
Age-based guidelines  
France, Liechtenstein and Portugal do not recommend systematical vaccination in healthy 
adults. The remaining European countries with age-based guidelines (n=24; 89%) advise 
vaccinating healthy adults with a minimum age of 50 years (n=5; 18.5%), 59 years (n=1; 4%), 
60 years (n=5; 18.5%) or 65 years (n=13; 48%). An upper age limit for vaccination was 
mentioned in Belgium and Luxembourg (both 85 years) and in the Netherlands (75 years).  
For primary vaccination of the healthy adult, four out of ten countries recommends the use of 
PPV23 only (n=11; 40.7%).  One country (Estonia) recommends the use of PCV13 only, while 
seven other countries (26%) recommended both PCV13 and PPV23 for primary vaccination. In 
four countries (15%), the type of vaccine recommended depends on the preference of the 
treating physician (Finland, Denmark, Lithuania, Slovenia). In Slovakia, the recommended 
vaccine type is not specified.  
 If both vaccines are recommended for primary vaccination, which is the case in nine countries, 
PCV13 is always administered first. The recommended interval between the two vaccinations 
(PCV13 and PPV23) differed between ≥8 weeks in Belgium, Denmark, Hungary, Luxembourg 
and Italy and ≥1 year in Finland, Greece and Austria. Slovakia recommends primary  
vaccination but did not specify the recommended vaccine type.  
Twelve countries (44.4%) do not advise a booster in healthy adults. Five national guidelines 
recommend a booster (18.5%), and five countries consider a booster under certain conditions 
(e.g. patients aged > 65y, who received their first vaccine at least 5 years ago when < 65y). In 
five guidelines, administration of boosters was not reported (18.5%). If a booster is given, all 
countries use PPV23.  
  
Risk-based guidelines  
  
The chronic disease group includes vaccination guidelines for chronic kidney (n=25; 89%), 
lung (n=25, 89%), heart (n=24, 86%), and liver disease (n=22, 79%) and diabetes mellitus 
(n=21, 75%). Mostly PCV13 and PPV23 or only PPV23 are recommended (see table 2). PCV13 
only is rarely used. A booster is recommended in 26 to 37% of the countries (depending on the 
underlying health condition), is considered in about 15% of the countries, and is not 
recommended in 26 to 35% of the countries, respectively. In one fifth of the countries, no 
booster guidelines were reported.   
In the immunocompromised population vaccination is recommended in the majority of the 
countries. Asplenia is the only condition for which all countries advise vaccination. 
Immunization of patients with immunodeficiency is recommended in 23 countries. About 65% 
of the countries recommend vaccination for HIV-patients, hematologic malignancies, patients 
taking immunosuppressive drugs and patients after solid organ transplant. 32% of these 
countries, recommend pneumococcal immunization in patients with parenchymatous 
 malignancies. The majority of the countries that recommend vaccinations in these 
immunocompromised patients (58 to 72% depending on the underlying condition), would 
vaccinate with PCV13 and PPV23. 10 to 20% of the countries recommend immunization with 
PPV23 only. Again, PCV13 only is rarely recommended. A booster is recommended in 40% of 
the countries that report risk-based guidelines (depending on the underlying condition). A 
booster is recommended for patients with asplenia in six out of ten countries. In up to 25% of 
the risk-based guidelines, no booster guidelines are reported.  
The third category includes various risk factors for pneumococcal disease. For patients with 
cerebrospinal fluid leak or a cochlear implant, most countries (89% and 82% respectively) 
recommend vaccination, mostly with PCV13 and PPV23 (64% and 62,5% respectively). Four 
out of ten countries advise a booster in this risk group. About 40% of the countries recommend 
vaccination for smokers and alcoholics, and two out of ten would vaccinate patients with 
occupational risk (such as welders), institutionalized patients and patients with neuromuscular 
disease. In these five previous risk groups, half of the countries vaccinates with PPV23 only, 
and roughly a quarter recommends administration of a booster. For patients with previous 
invasive pneumococcal disease or pneumococcal pneumonia, vaccination is only recommended 
in three countries. Sweden and Liechtenstein are the only countries that would vaccinate 
patients with BMI > 40 kg/m². Norway and the Netherlands would consider pneumococcal 
immunization for patients with celiac disease, homeless patient groups and drug addicts.    
    
Discussion  
  
In this study, comparing the European guidelines for pneumococcal vaccination of adult patients 
at elevated risk for pneumococcal infection, we observed a great variability in vaccine 
recommendation despite increasing evidence of pneumococcal vaccine being effective in older 
adults.   
 Although no concluding evidence about the efficacy of PPV23 was reported in a Cochrane 
review (probably due to a lack of statistical power), the benefit of PPV23 was more pronounced 
when limiting the analysis to trials that assessed the incidence of vaccine-serotype disease. (11)  
Also, two recent meta-analyses showed PPV23 vaccine efficacy. (9, 12) Falkenhorst et al (2017) 
found a significant vaccine efficacy of 73% for IPD and of 64% for pneumococcal pneumonia 
in patients aged ≥ 60 years. (9) Kraicer-Melamed et al. (2016)  described a 50% vaccine efficacy 
for IPD in patients aged  ≥ 50 years. (12) The authors state that the use of recent and high quality 
data led to this results, contrary to the Cochrane review.   
  
Concerning PCV13, the most important study is the CAPITA trial (2015). This 
placebocontrolled study analyzed the vaccine efficacy of PCV13 in 85.000 patients aged ≥ 65 
years.  A vaccine efficacy of 45.6%, 45% and 75 % in the prevention of respectively vaccine-
type community acquired pneumonia, non-bacteremic and non-invasive community-acquired 
pneumonia, and invasive pneumococcal disease was demonstrated. Efficacy persisted 
throughout the trial (mean follow-up 3,97 years) suggesting that PCV13 should be part of the 
vaccination program in older adults. (13)  However, the results of the CAPITA-trial should be 
interpreted with caution as patients with immunodeficiency were excluded and as it took place 
before implementation of childhood pneumococcal immunization in the Netherlands. The latter 
thereby ignores the herd effect, and the study possibly overestimates the efficacy of PCV13. (9)  
The CAPITA-trial also examined the long-term immunogenicity of PCV13 in pneumococcal 
vaccine–naive older adults, demonstrating high antibody titers during the first two years 
following vaccination after a single dose of PCV13.  In adults aged ≥80 years, weaker responses 
were observed, but antibody levels remained above baseline. (14)  
  
Cost-effectiveness analysis are often issued by health authorities to substantiate inclusion of 
pneumococcal vaccination in the adult vaccination program with (partial) reimbursement of the 
 costs. In 2012, the Infection Prevention Institute in Poland performed a cost-effectiveness 
analysis on the implementation of a public vaccination program with PPV23 only in the elderly 
aged ≥65 years. When taking into account the medical and economic burden of pneumococcal 
disease of that time, presuming a PPV23-vaccine efficacy of 64% for IPD in elderly and 
assuming a 50% reimbursement of the PPV23 vaccine from their national health fund, they 
concluded that the use of PPV23 in healthy elderly, would be highly cost-effective. (4) A 
costeffectiveness analysis in the United Kingdom (2015) stated that adding PCV13 to the 
existing vaccination program with PPV23 in healthy elderly would substantially raise costs of 
immunization programs and would not be cost-effective. (15)  
  
Despite some disadvantages of PPV23 (lack of development of an immune memory, reduced 
immunogenicity in the elderly), and some conflicting results on efficacy of this vaccine as 
mentioned above, the more recent systematic reviews and this cost-effectiveness analysis 
provide arguments for a vaccination strategy in the healthy elderly that includes PPV23.   
Furthermore, as there is to our knowledge no study comparing the efficacy of PCV13 and 
PPV23 in elderly patients, and considering the economic aspect and weaknesses of the 
CAPITA-trial mentioned above, updating vaccination guidelines and recommending the use of 
both PCV13 and PPV23 for the healthy elderly (as done in the United States by the Advisory 
Committee on Immunization Practices (ACIP) in 2014), should be done cautiously. (16) More 
studies on pneumococcal vaccination of the healthy elderly are needed, including a new efficacy 
trial for PCV13 that takes into account the herd protection effect.  
  
As vaccine-induced immunity wanes after a few years, considering the lack of development of 
an immune memory, a booster vaccine can be considered. The efficacy of boosters however is 
uncertain, mainly because a state of hypo-responsiveness or immune tolerance is described 
 following revaccination with PPV23. This especially seems relevant if a booster is administered 
within 5 years after primary vaccination. Musher et al. demonstrated that persons who received  
PPV23 within one year, almost did not respond to revaccination, and those who had received 
PPV23 within 1 to 5 years responded less well than those who had no previous or more remote 
vaccination. (17, 18) Another systematic review comparing the effectiveness, immunogenicity 
and safety of revaccination with PPV23 in persons aged ≥ 50 years, demonstrated a reduced 
antibody response during the first months after revaccination (thereafter, immunogenicity of 
primary and repeated vaccination was comparable). There were no major safety concerns 
regarding revaccination. (19) All of the studies mentioned above however, are immunogenicity 
studies that evaluate antibody responses after immunization, therefore lacking clinical 
endpoints or data about clinical effectiveness. As the available evidence concerning 
revaccination with PPV23 is not unambiguous, neither are the guidelines concerning the use of 
boosters in healthy elderly.   
  
The strength of this article lies in the comprehensive overview of 31 European countries and 
the United States, which is to our knowledge the largest comprehensive overview up to present. 
A limitation of the study includes the use of Google Translate or interpreters, and thus the lack 
of a formal forward-backward translation. Although this could have led to incorrect translations 
or interpretations, the immunization guidelines were very straightforward, often written in 
bullet points.   
     
 Conclusion  
  
Pneumococcal vaccination has greatly reduced incidence of vaccine-type pneumococcal 
morbidity and mortality. There is great variability in European pneumococcal vaccination 
guidelines for adults, regarding age, risk groups, and vaccine type. Most countries did not have 
clear recommendations about the administration of boosters. For ease of implementation, 
European unification of the immunization guidelines is needed. This remains difficult despite 
increasing evidence on pneumococcal vaccine effectiveness in elderly.  
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 Table to be included in the manuscript 
Table 1 – Resume age-based guidelines   
  
Age-based guidelines (healthy population) - n=27  
N  %  Countries  
  
Recommended starting age of vaccination  
   
>/= 50y  5  18.5  Austria, Estonia, Hungary, Lithuania, Poland  
>/= 59y  1  3.7  Slovakia  
>/= 60y  5  18.5  Bulgaria, Germany, Iceland, the Netherlands, Spain  
>/= 65y  13  48.1  Belgium, Czech Republic, Denmark, Finland, Greece, Ireland, Italy, 
Luxembourg, Malta, Norway, Slovenia, Sweden, United Kingdom  
Vaccination not recommended  
  
Upper limit of age for vaccination reported :  
3  11.1  France, Liechtenstein, Portugal  
  
  
Vaccine type recommended in primary vaccination   
3  11.1  Belgium, Luxembourg, the Netherlands  
PCV13  1  3.7  Estonia  
PPV23  11  40.7  Bulgaria, Germany, Iceland, Ireland, Malta, the Netherlands, Norway, 
Poland, Spain, Sweden, United Kingdom  
PCV13 and PPV23  7  25.9  Austria, Belgium, Czech Republic, Greece, Hungary, Luxembourg  
Several options possible  4  14.8  Denmark, Finland, Lithuania, Slovenia   
 Recommended but vaccine type not specified  1  3.7  Slovakia  
  




Administration of booster  
Booster recommended  5  18.5  Czech Republic, Denmark, Estonia, the Netherlands, Norway  
No booster recommended  12  44.4  Austria, Belgium, France, Germany, Iceland, Italy, Liechtenstein, 
Luxembourg, Malta, Portugal, Sweden, United Kingdom  
Booster to consider  5  18.5  Bulgaria, Ireland, Lithuania, Slovenia, Spain  
 Not reported  5  18.5  Finland, Greece, Hungary, Poland, Slovakia  
  
Type of vaccine used for booster  
 PCV13  10  100  Bulgaria, Czech Republic, Denmark, Estonia, Ireland, Lithuania, the  
Netherlands, Norway, Slovenia, Spain  
 PPV23  0  0    
  
n: number of countries; PPV23: pneumococcal polysaccharide vaccine; PCV13 pneumococcal conjugate vaccine   
  
  
    -   Interval between the two vaccines ≥ 8 weeks  5   55.6   Belgium, Denmark, Hungary, Luxembourg, Italy   
    -   Interval between the two  vaccines ≥ 1 year  3   33.3   Austria, Finland, Greece   
    -   Interval not specified   1   11.1   Czech Republic   
PPV23 first   0   0     
 Table to be included in the manuscript 
 1  Table 2 – Resume risk factor-based guidelines  
Risk factor-based guidelines (n = 28)  
  Vaccination  
recommended  
 n  %  
Vaccination 
to consider  
 Vaccine type   




n  %  n  %  n  %  n  %  n  %  
Chronic disease   
Chronic kidney disease  
 
2  7.1  1  3.7  7  25.9  14  51.9  
 
18.5  10  
 
 Chronic lung disease  2  7.1  1  3.7  8  29.6  12  44.4  22.2  8  
Chronic heart disease  
 
2  7.1  1  3.8  7  26.9  12  46.2  
 
23.1  7  
  Chronic liver disease  2  7.1  1  4.2  7  29.2  11  45.8  20.8  7  
Diabetes mellitus  21  75  2  7.1  1  4.3  8  34.8  9  39.1  5  21.7  6  
  
Immunocompromising conditions  
Asplenia  
 
0  0  1  3.6  4  14.3  18  64.3  
 
17.9  16   57.1  3  
   Immunodeficiency  2  7.1  1  4  2  8  16  64  24  10   40  5  
HIV  
 
1  3.6  1  5  4  20  12  60  
 
15  7  
6  
6    
 
 
Hematological malignancy  1  3.6  1  5.3  3  15.8  11  57.9  21.1  7  
Immunosuppressive therapy  
 
2  7.1  1  5  3  15  12  60  
 
20  7  
7  
5    
 
 
Solid organ transplant  1  3.6  1  5.6  2  11.1  11  61.1  22.2  8  
Parenchymatous malignancy  9  32.1  2  7.1  0  0  1  9.1  8  72.7  2  18.2  5   45.5  3  
  
Other risk factors for pneumococcal disease  
CSF-leak  
 
0  0  1  4  5  16  16  64  
 
16  10  
7  
7   
 Cochlear implant  1  3.6  1  4.2  4  16.7  15  62.5  16.7  10  
Alcoholism  
 
2  7.1  0  0  5  35.7  6  42.9  
 
21.4  2   14.3  5  
  Smoking  1  3.6  0  0  4  36.4  6  54.5  9.1  3   27.3  4  
Occupational risk  6  21.4  1  3.6  0  0  3  42.9  3  42.9  
 
14.3  2   28.6  2  
  Institutionalized patients  5  17.9  0  0  0  0  2  40  0  0  60  1   20  0  
Neuromuscular disease  5  17.9  0  0  0  0  3  60  1  20  
 
20  1   20  4  
  Medical history of IPD   3  10.7  2  7.1  0  0  0  0  4  80  20  3   60  1  
BMI > 40 kg/m²  2  7.1  0  0  1  50  1  50  0  0  
 
0  0   0  2  
  Celiac disease  0  0  2  7.1  0  0  0  0  1  50  50  0   0  1  
Homeless patients  0  0  2  7.1  0  0  0  0  1  50  1  50  0   0  1  
  Drug addicts  0  0  2  7.1  0  0  0  0  1  50  1  50  0   0  1  
 2    
3 BMI: body mass index; CSF: cerebrospinal fluid; HIV: human immunodeficiency virus; IPD: 
invasive pneumococcal disease; n: number of countries; PPV23: pneumococcal  
4 polysaccharide vaccine; PCV13 pneumococcal conjugate vaccine   
 5    
25   89.3   
25   89.3   
24   85.7   
22   78.6   
28   100   
23   82.1   
19   67.9   
18   64.3   
18   64.3   
17   60.7   
25   89.3   
23   82.1   
12   42.9   
10   35.7   
  6    
 
